The biotech industry is ripe with great investment opportunities due to technological advancements such as artificial intelligence (AI), market demand, and favorable regulatory support. Companies developing cutting-edge treatments such as gene editing, mRNA therapies, and personalized medicine appear to be attracting investor and analyst attention.
While investing in biotech stocks can be risky due to clinical trial failures and regulatory hurdles, successful drug approvals can result in massive stock gains. Let’s look at two such growth stocks that have the potential to generate significant long-term returns.
